Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
Ascentage Pharma announced that 17 clinical advancements of its key drug candidates, including Olverembatinib and Lisaftoclax, will be featured at the 31st European Hematology Association Congress in June 2026. The presentations cover ongoing clinical studies in chronic myeloid leukemia (CML), chronic lymphocytic leukemia/small lymphocytic lymphoma…